Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation
To understand the mechanism involved in gefitinib resistance, we established gefitinib-resistant human HCC827/GR-8-1 cell line from the parental HCC827 cell line. We compared the micro-RNA expression profiles of the HCC827 cells HCC827/GR-8-1 using Agilent micro-RNA microarrays. The micro-RNAs, such...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-03-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317691659 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839595988005683200 |
|---|---|
| author | Yong Hu Xiaobing Qin Dali Yan Haixia Cao Leilei Zhou Fan Fan Jialan Zang Jie Ni Xiaoyue Xu Huanhuan Sha Siwen Liu Shaorong Yu Jianzhong Wu Rong Ma Jifeng Feng |
| author_facet | Yong Hu Xiaobing Qin Dali Yan Haixia Cao Leilei Zhou Fan Fan Jialan Zang Jie Ni Xiaoyue Xu Huanhuan Sha Siwen Liu Shaorong Yu Jianzhong Wu Rong Ma Jifeng Feng |
| author_sort | Yong Hu |
| collection | DOAJ |
| description | To understand the mechanism involved in gefitinib resistance, we established gefitinib-resistant human HCC827/GR-8-1 cell line from the parental HCC827 cell line. We compared the micro-RNA expression profiles of the HCC827 cells HCC827/GR-8-1 using Agilent micro-RNA microarrays. The micro-RNAs, such as the miR-149-5p, were up- or downregulated and associated with acquired gefitinib resistance. Quantitative real-time polymerase chain reaction was then performed to verify the expression patterns of different micro-RNAs. The result showed that miR-149-5p was upregulated in the HCC827/GR-8-1 cell line. To investigate the biological function of miR-149-5p in non–small cell lung cancer cells acquired gefitinib resistance, we examined cell proliferation using a cell counting kit-8 assay. Cell viability was evaluated after the miR-149-5p mimics, inhibitors, and negative control were separately transfected into the non–small cell lung cancer cells. The results showed that the non–small cell lung cancer cells transfected with miR-149-5p mimics exhibited reduced cell motility. The drug-sensitivity assay results revealed that the overexpression of miR-149-5p effectively evaluates the half maximal inhibitory concentration values of the cell in response to gefitinib, and the downregulation of miR-149-5p can attenuate the half maximal inhibitory concentration values of the cell lines in response to gefitinib. Furthermore, the levels of miR-149-5p in the HCC827 and HCC827/GR-8-1 cells were inversely correlated with caspase-3 expression. In conclusion, this study revealed that miR-149-5p is upregulated in the HCC827/GR-8-1 cells and involved in the acquired gefitinib resistance. |
| format | Article |
| id | doaj-art-e9f44c62f08a445595d8b5c97c98a786 |
| institution | Matheson Library |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-e9f44c62f08a445595d8b5c97c98a7862025-08-02T22:26:55ZengSAGE PublishingTumor Biology1423-03802017-03-013910.1177/1010428317691659Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulationYong Hu0Xiaobing Qin1Dali Yan2Haixia Cao3Leilei Zhou4Fan Fan5Jialan Zang6Jie Ni7Xiaoyue Xu8Huanhuan Sha9Siwen Liu10Shaorong Yu11Jianzhong Wu12Rong Ma13Jifeng Feng14Department of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Oncology, Xuzhou First People’s Hospital, Xuzhou, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaDepartment of Clinical Cancer Research Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, ChinaTo understand the mechanism involved in gefitinib resistance, we established gefitinib-resistant human HCC827/GR-8-1 cell line from the parental HCC827 cell line. We compared the micro-RNA expression profiles of the HCC827 cells HCC827/GR-8-1 using Agilent micro-RNA microarrays. The micro-RNAs, such as the miR-149-5p, were up- or downregulated and associated with acquired gefitinib resistance. Quantitative real-time polymerase chain reaction was then performed to verify the expression patterns of different micro-RNAs. The result showed that miR-149-5p was upregulated in the HCC827/GR-8-1 cell line. To investigate the biological function of miR-149-5p in non–small cell lung cancer cells acquired gefitinib resistance, we examined cell proliferation using a cell counting kit-8 assay. Cell viability was evaluated after the miR-149-5p mimics, inhibitors, and negative control were separately transfected into the non–small cell lung cancer cells. The results showed that the non–small cell lung cancer cells transfected with miR-149-5p mimics exhibited reduced cell motility. The drug-sensitivity assay results revealed that the overexpression of miR-149-5p effectively evaluates the half maximal inhibitory concentration values of the cell in response to gefitinib, and the downregulation of miR-149-5p can attenuate the half maximal inhibitory concentration values of the cell lines in response to gefitinib. Furthermore, the levels of miR-149-5p in the HCC827 and HCC827/GR-8-1 cells were inversely correlated with caspase-3 expression. In conclusion, this study revealed that miR-149-5p is upregulated in the HCC827/GR-8-1 cells and involved in the acquired gefitinib resistance.https://doi.org/10.1177/1010428317691659 |
| spellingShingle | Yong Hu Xiaobing Qin Dali Yan Haixia Cao Leilei Zhou Fan Fan Jialan Zang Jie Ni Xiaoyue Xu Huanhuan Sha Siwen Liu Shaorong Yu Jianzhong Wu Rong Ma Jifeng Feng Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation Tumor Biology |
| title | Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation |
| title_full | Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation |
| title_fullStr | Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation |
| title_full_unstemmed | Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation |
| title_short | Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation |
| title_sort | genome wide profiling of micro rna expression in gefitinib resistant human lung adenocarcinoma using microarray for the identification of mir 149 5p modulation |
| url | https://doi.org/10.1177/1010428317691659 |
| work_keys_str_mv | AT yonghu genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT xiaobingqin genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT daliyan genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT haixiacao genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT leileizhou genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT fanfan genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT jialanzang genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT jieni genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT xiaoyuexu genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT huanhuansha genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT siwenliu genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT shaorongyu genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT jianzhongwu genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT rongma genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation AT jifengfeng genomewideprofilingofmicrornaexpressioningefitinibresistanthumanlungadenocarcinomausingmicroarrayfortheidentificationofmir1495pmodulation |